Majid Mughal, MD
Interventional Cardiology · Okemos, MINPI 1992750723
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $173,342 of the $196,426 with a category attached, or 88.2%. United Therapeutics Corporation accounts for 66.3% of it on its own, with 28 other manufacturers making up the rest. Among interventional cardiology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $379.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$130K
- Bayer$55K
- Medtronic$6K
- Edwards Lifesciences$972
- Amgen$737
- Novartis$636
- plus $3K from 23 others
Across 60 payments — averaging $4036.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$162K
- United Therapeutics Corporation$58K
- AstraZeneca$22K
What the payments were for
- Consulting fees$1440%
- Speaking & faculty fees$173,34288%
- Travel & lodging$9,7065%
- Food & beverage$12,8937%
- Education$3410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 131 | $130,140 |
| Bayer | 51 | $54,826 |
| Medtronic(2 entities) | 136 | $5,721 |
| Edwards Lifesciences | 17 | $972 |
| Amgen | 31 | $737 |
| Novartis | 44 | $636 |
| Abbott | 11 | $549 |
| Boston Scientific | 18 | $530 |
| Johnson & Johnson | 20 | $362 |
| Inari Medical, Inc. | 6 | $275 |
| E.r. Squibb & Sons, L.L.C. | 6 | $241 |
| AstraZeneca | 5 | $217 |
| Pfizer | 10 | $159 |
| Actelion Pharmaceuticals US, Inc. | 3 | $158 |
| Baxter Healthcare | 4 | $152 |
| Abiomed | 2 | $144 |
| Alnylam Pharmaceuticals Inc. | 1 | $104 |
| Merck | 3 | $77 |
| Stryker | 2 | $75 |
| Boehringer Ingelheim | 4 | $69 |
| Shockwave Medical, Inc | 2 | $65 |
| Atricure, Inc. | 1 | $46 |
| EKOS Corporation | 2 | $35 |
| Vericel Corporation | 2 | $33 |
| Teleflex LLC | 2 | $31 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Livanova USA, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Biosense Webster, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$54,259
- TYVASO$39,559
- REMODULIN$17,180
- ORENITRAM$12,472
- COREVALVE EVOLUT R$2,061
- CoreValve Evolut$1,231
- SAPIEN 3 Ultra RESILIA$392
- FLOWTRIEVER CATHETER, S$165
- CT THROMBECTOMY SYSTEM KIT$165
- CARDIOMEMS$146
- Impella$119
- AMVUTTRA$104
How this compares
$196,426 in reported general payments places this provider in the 90th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 158 | $2,140,567 |
| Orenitram ErTreprostinil Diolamine | 52 | $1,224,174 |
| OfevNintedanib Esylate | 65 | $855,070 |
| OpsumitMacitentan | 50 | $629,731 |
| Tyvaso DpiTreprostinil | 27 | $627,375 |
| EliquisApixaban | 405 | $470,973 |
| EntrestoSacubitril/Valsartan | 280 | $293,801 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 301 | $273,982 |
| FarxigaDapagliflozin Propanediol | 157 | $162,657 |
| ZemairaAlpha-1-Proteinase Inhibitor | 12 | $135,332 |
| XareltoRivaroxaban | 80 | $113,787 |
| JardianceEmpagliflozin | 77 | $99,125 |
| Tadalafil | 59 | $40,678 |
| Ambrisentan | 15 | $32,732 |
| Repatha SureclickEvolocumab | 34 | $28,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $54,826 | $2,140,567158 claims |
| Boehringer IngelheimOfev, Jardiance, Spiriva Respimat, Stiolto Respimat | $69 | $981,266179 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $158 | $629,73150 claims |
| PfizerEliquis | $159 | $470,973405 claims |
| NovartisEntresto | $636 | $293,801280 claims |
| AstraZenecaFarxiga, Symbicort | $217 | $181,221215 claims |
| Johnson & JohnsonXarelto | $362 | $113,78780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Okemos
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
- Khaldoon AlaswadDetroit$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.